Related references
Note: Only part of the references are listed.The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
M. O. Holmstrom et al.
LEUKEMIA (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Evaluation of Long-Term Outcomes of Microsatellite Instability Status in an Asian Cohort of Sporadic Colorectal Cancers
Winson Jianhong Tan et al.
JOURNAL OF GASTROINTESTINAL CANCER (2018)
Rejection versus escape: the tumor MHC dilemma
Federico Garrido et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Maria Parkhurst et al.
CLINICAL CANCER RESEARCH (2017)
The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction
Jennifer G. Abelin et al.
IMMUNITY (2017)
In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes
Julien Schmidt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
Junhun Cho et al.
ONCOTARGET (2017)
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model
Barbara Schroers et al.
ONCOTARGET (2017)
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Anita Sveen et al.
GENOME MEDICINE (2017)
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies
Ryan J. Hartmaier et al.
GENOME MEDICINE (2017)
K27M-mutant histone-3 as a novel target for glioma immunotherapy
Katharina Ochs et al.
ONCOIMMUNOLOGY (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Else M. Inderberg et al.
ONCOIMMUNOLOGY (2017)
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Florine A. a Eggink et al.
ONCOIMMUNOLOGY (2017)
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
Marco Donia et al.
CANCER RESEARCH (2017)
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2017)
Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor
Kenji Fujiyoshi et al.
ANTICANCER RESEARCH (2017)
Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing
Takahiro Karasaki et al.
CANCER SCIENCE (2017)
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation
Matthias Leisegang et al.
CLINICAL CANCER RESEARCH (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis
Minoru Koi et al.
GASTROENTEROLOGY (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Targeting human melanoma neoantigens by T cell receptor gene therapy
Matthias Leisegang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
David Tougeron et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum et al.
MODERN PATHOLOGY (2016)
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
Drew C. Deniger et al.
MOLECULAR THERAPY (2016)
Neoantigen landscape dynamics during human melanoma-T cell interactions
Els M. E. Verdegaal et al.
NATURE (2016)
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes
Amalie Kai Bentzen et al.
NATURE BIOTECHNOLOGY (2016)
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Alena Gros et al.
NATURE MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Erlend Stronen et al.
SCIENCE (2016)
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
Michal Bassani-Sternberg et al.
NATURE COMMUNICATIONS (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns et al.
CANCER DISCOVERY (2016)
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Stephen J. Blake et al.
CANCER DISCOVERY (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (vol 15, pg 857, 2016)
Marios Giannakis et al.
CELL REPORTS (2016)
Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
Sarah Knocke et al.
CELL REPORTS (2016)
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
David Tougeron et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Low Level of Microsatellite Instability Correlates with Poor Clinical Prognosis in Stage II Colorectal Cancer Patients
Ehsan Nazemalhosseini Mojarad et al.
JOURNAL OF ONCOLOGY (2016)
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines
Spencer D. Martin et al.
PLOS ONE (2016)
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Peter Bailey et al.
SCIENTIFIC REPORTS (2016)
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
Cyrille J. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
Elena Maccaroni et al.
ONCOTARGET (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
Stephen Q. Wong et al.
ONCOTARGET (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Immunological hallmarks of stromal cells in the tumour microenvironment
Shannon J. Turley et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells
Sheena Pinto et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
Fei Duan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Mahesh Yadav et al.
NATURE (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression
J. Liang et al.
BRITISH JOURNAL OF CANCER (2013)
It's the Peptide-MHC Affinity, Stupid
Thomas Kammertoens et al.
CANCER CELL (2013)
Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas
Sebastian Bender et al.
CANCER CELL (2013)
Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity
Boris Engels et al.
CANCER CELL (2013)
T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer
Kathrin Bauer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence
Brian M. Olson et al.
EXPERT REVIEW OF VACCINES (2012)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Jeremy Schwartzentruber et al.
NATURE (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
Jose Pulido et al.
NATURE BIOTECHNOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Tae-Won Kang et al.
NATURE (2011)
Repetitive Antigen Stimulation Induces Stepwise Transcriptome Diversification but Preserves a Core Signature of Memory CD8+ T Cell Differentiation
Thomas C. Wirth et al.
IMMUNITY (2010)
Immune evasion of microsatellite unstable colorectal cancers
Matthias Kloor et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Accumulation of driver and passenger mutations during tumor progression
Ivana Bozic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation
Iris Caramalho et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
The MHC class I peptide repertoire is molded by the transcriptome
Marie-Helene Fortier et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Persistence of multiple tumor-specific T-Cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
JH Zhou et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer
Y Ichiki et al.
JOURNAL OF IMMUNOLOGY (2004)
Bystander elimination of antigen loss variants in established tumors
MT Spiotto et al.
NATURE MEDICINE (2004)
CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation
MS Sharkey et al.
CANCER RESEARCH (2004)
Immunogenicity of constitutively active V599EBRaf
MH Andersen et al.
CANCER RESEARCH (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:: Correlation with antibody responses
S Gnjatic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Genomic medicine - Hereditary colorectal cancer
HT Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Immunotherapy: past, present and future
TA Waldmann
NATURE MEDICINE (2003)
Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers
Y Shono et al.
BRITISH JOURNAL OF CANCER (2003)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution
Y Ionov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
